Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abivax SA
Capital Expenditures
Abivax SA
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Capital Expenditures
-€643k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
Valneva SE
PAR:VLA
|
Capital Expenditures
-€4.5m
|
CAGR 3-Years
47%
|
CAGR 5-Years
25%
|
CAGR 10-Years
-5%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Capital Expenditures
-€3.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-16%
|
|
|
Inventiva SA
PAR:IVA
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Capital Expenditures
-$3.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
42%
|
CAGR 10-Years
2%
|
|
|
DBV Technologies SA
PAR:DBV
|
Capital Expenditures
-$538k
|
CAGR 3-Years
11%
|
CAGR 5-Years
28%
|
CAGR 10-Years
19%
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Capital Expenditures?
Capital Expenditures
-643k
EUR
Based on the financial report for Dec 31, 2025, Abivax SA's Capital Expenditures amounts to -643k EUR.
What is Abivax SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
5%
Over the last year, the Capital Expenditures growth was 0%. The average annual Capital Expenditures growth rates for Abivax SA have been -26% over the past three years , 6% over the past five years , and 5% over the past ten years .
